Vistagen Therapeutics has announced positive results from a Phase 2A study of its PH80 nasal spray for the acute treatment of hot flashes in women diagnosed with menopausal hot flashes. In the randomized, double-blind, placebo-controlled exploratory study, 36 subjects self-administered PH80 intranasally up to four times daily for four consecutive weeks. The spray reduced the daily number of hot flashes compared to the placebo at week one and this improvement was maintained through each treatment week until the end of treatment. PH80 also significantly reduced severity and disruption in function related to hot flashes during treatment as compared with placebo. Vistagen is developing PH80 as a potential new treatment for acute management of menopausal hot flashes and potentially migraine.